Bolt Biotherapeutics Reports Q2 2026 Results, Business Update

What Happened

• On August 11, 2026, Bolt Biotherapeutics, Inc. (BOLT) filed a Form 8‑K (Item 2.02) to announce its financial results for the quarter ended June 30, 2026 and to provide a business update. The company furnished a press release dated August 11, 2026 as Exhibit 99.1. The 8‑K notes that the information and exhibit are furnished (not “filed”) under the Exchange Act and therefore are not subject to certain liability provisions.

Key Details

• Filing date: August 11, 2026 (Form 8‑K, Item 2.02 and Item 9.01).
• Quarter covered: Second quarter ended June 30, 2026.
• Exhibit: Press release dated August 11, 2026 furnished as Exhibit 99.1 (contains the detailed financial results and business update).
• Signature: Report signed by William P. Quinn, President, Chief Executive Officer and Chief Financial Officer.

Why It Matters

• This filing signals that Bolt has released its quarterly earnings and operational update; those details (revenue, R&D spend, cash position, pipeline progress) are in the press release (Exhibit 99.1) and can materially affect investor sentiment and the stock price.
• Retail investors should read the attached press release for the specific financial figures and management commentary; because the exhibit is furnished (not filed), it is provided for information but is not subject to certain securities-act liabilities.